Legal & General Group Plc Buys Shares of 711,233 Elanco Animal Health Incorporated $ELAN

Legal & General Group Plc acquired a new position in Elanco Animal Health Incorporated (NYSE:ELAN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 711,233 shares of the company’s stock, valued at approximately $17,503,000.

A number of other hedge funds also recently bought and sold shares of ELAN. BlackRock Inc. purchased a new position in Elanco Animal Health in the second quarter worth about $1,202,198,000. T. Rowe Price Investment Management Inc. increased its holdings in Elanco Animal Health by 11.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock valued at $797,197,000 after buying an additional 3,717,404 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Elanco Animal Health by 1.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 25,082,545 shares of the company’s stock worth $567,622,000 after acquiring an additional 373,869 shares during the period. UBS Group AG raised its position in Elanco Animal Health by 56.7% in the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after acquiring an additional 5,961,457 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Elanco Animal Health by 7.3% during the 4th quarter. Geode Capital Management LLC now owns 9,425,533 shares of the company’s stock valued at $213,343,000 after acquiring an additional 640,098 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Insider Activity at Elanco Animal Health

In related news, CFO Robert M. Vanhimbergen bought 4,200 shares of the company’s stock in a transaction on Friday, August 7th. The shares were acquired at an average cost of $23.08 per share, for a total transaction of $96,936.00. Following the purchase, the chief financial officer directly owned 137,516 shares of the company’s stock, valued at approximately $3,173,869.28. The trade was a 3.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Lawrence Erik Kurzius bought 40,000 shares of Elanco Animal Health stock in a transaction dated Thursday, August 20th. The shares were bought at an average cost of $23.40 per share, for a total transaction of $936,000.00. Following the completion of the transaction, the director owned 188,647 shares of the company’s stock, valued at approximately $4,414,339.80. This trade represents a 26.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 63,198 shares of company stock worth $1,473,109 over the last ninety days. 1.14% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ELAN has been the subject of several recent research reports. Weiss Ratings lowered Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, August 20th. Morgan Stanley raised their price target on Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 22nd. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. UBS Group increased their price target on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Finally, Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $29.09.

Elanco Animal Health Price Performance

ELAN opened at $24.16 on Monday. The business has a fifty day moving average of $24.62 and a 200 day moving average of $24.00. Elanco Animal Health Incorporated has a 52-week low of $17.11 and a 52-week high of $27.98. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The stock has a market cap of $12.07 billion, a P/E ratio of -58.93, a PEG ratio of 1.44 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The business’s revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm posted $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.